Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naive Patients With Advanced or Recurrent Non-squamous NSCLC

Next Previous
Trial Profile

Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naive Patients With Advanced or Recurrent Non-squamous NSCLC

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Innovent Biologics

Most Recent Events

  • 18 Jun 2020 According to an Innovent Biologics media release, BYVASDA (bevacizumab biosimilar) has been officially approved by the National Medical Products Administration (NMPA) of China for patients with advanced non-small cell lung cancer and metastatic colorectal cancer in China.
  • 30 Mar 2020 According to an Innovent Biologics Media Release, NDA approval is expected in 2020.
  • 19 Sep 2019 According to an Innovent Biologics Media Release, data from this trial were presented in an oral session at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top